FREQUENT HOMOZYGOUS DELETIONS OF TYPE I INTERFERON GENES IN PLEURAL MESOTHELIOMA CONFER SENSITIVITY TO ONCOLYTIC MEASLES VIRUS.
暂无分享,去创建一个
S. Minvielle | F. Tangy | A. Magnan | C. Blanquart | M. Grégoire | D. Fradin | C. Meiller | J. Bennouna | D. Jean | J. Fonteneau | Nicolas Boisgerault | Tiphaine Delaunay | Marion Grard | C. Achard | Tacien Petithomme | C. Chatelain | S. Dutoit | Pierre‐Joseph Royer | Lisa Quetel | L. Cellerin
[1] E. Thompson,et al. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy , 2018, Journal of the National Cancer Institute.
[2] J. Bell,et al. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy , 2018, EBioMedicine.
[3] E. Chiocca,et al. Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. , 2018, Oncoimmunology.
[4] J. Aerts,et al. Novel insights into mesothelioma biology and implications for therapy , 2017, Nature Reviews Cancer.
[5] E. Galanis,et al. Potential and clinical translation of oncolytic measles viruses , 2017, Expert opinion on biological therapy.
[6] F. Tangy,et al. Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells , 2016, Oncoimmunology.
[7] J. Zucman‐Rossi,et al. Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma , 2016, Clinical Cancer Research.
[8] S. Pastorino,et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma , 2016, Proceedings of the National Academy of Sciences.
[9] F. Tangy,et al. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response , 2015, Oncotarget.
[10] F. Tangy,et al. Induction of Immunogenic Tumor Cell Death by Attenuated Oncolytic Measles Virus , 2015 .
[11] A. Oberg,et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. , 2015, Cancer research.
[12] A. Marchini,et al. Oncolytic parvoviruses: from basic virology to clinical applications , 2015, Virology Journal.
[13] M. Diamond,et al. Deficient IFN Signaling by Myeloid Cells Leads to MAVS-Dependent Virus-Induced Sepsis , 2014, PLoS pathogens.
[14] C. Rice,et al. Interferon-stimulated genes: a complex web of host defenses. , 2014, Annual review of immunology.
[15] E. Chiocca,et al. Glioma virus therapies between bench and bedside. , 2014, Neuro-oncology.
[16] F. Galateau-Sallé,et al. Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition , 2014, Clinical Cancer Research.
[17] U. Lauer,et al. Primary resistance phenomena to oncolytic measles vaccine viruses. , 2013, International journal of oncology.
[18] F. Tangy,et al. Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells , 2013, Oncoimmunology.
[19] F. Tangy,et al. Antitumor Virotherapy by Attenuated Measles Virus (MV) , 2013, Biology.
[20] F. Tangy,et al. Measles Virus Vaccine–Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells , 2013, Clinical Cancer Research.
[21] F. Stubenrauch,et al. Innate Immune Defense Defines Susceptibility of Sarcoma Cells to Measles Vaccine Virus-Based Oncolysis , 2013, Journal of Virology.
[22] J. Bond,et al. Measles virus causes immunogenic cell death in human melanoma , 2011, Gene Therapy.
[23] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[24] S. Russell,et al. ONCOLYTIC VIROTHERAPY , 2012, Nature Biotechnology.
[25] F. Galateau-Sallé,et al. Molecular changes in mesothelioma with an impact on prognosis and treatment. , 2012, Archives of pathology & laboratory medicine.
[26] Christopher T. Jones,et al. A diverse array of gene products are effectors of the type I interferon antiviral response , 2011, Nature.
[27] A. Krasinskas,et al. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. , 2011, American journal of clinical pathology.
[28] A. Scherpereel,et al. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. , 2011, The American journal of pathology.
[29] D. Knight,et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. , 2009, American journal of respiratory and critical care medicine.
[30] F. Galateau-Sallé,et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas , 2008, Virchows Archiv.
[31] F. Tangy,et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. , 2008, Cancer research.
[32] Simion I. Chiosea,et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas , 2008, Modern Pathology.
[33] C. Shuler,et al. Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas. , 2006, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[34] S. Russell,et al. High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus , 2004, Cancer Research.
[35] L. Mollet,et al. A Molecularly Cloned Schwarz Strain of Measles Virus Vaccine Induces Strong Immune Responses in Macaques and Transgenic Mice , 2003, Journal of Virology.
[36] Z. Fishelson,et al. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. , 2003, Molecular immunology.
[37] M. Ladanyi,et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] J. Hiscott,et al. Transcriptional Profiling of Interferon Regulatory Factor 3 Target Genes: Direct Involvement in the Regulation of Interferon-Stimulated Genes , 2002, Journal of Virology.
[39] T. Taniguchi,et al. Gene induction pathways mediated by distinct IRFs during viral infection. , 2001, Biochemical and biophysical research communications.
[40] J. Fletcher,et al. Codeletion of p15 and p16 in primary malignant mesothelioma. , 1995, Oncogene.
[41] O. Olopade,et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.
[42] Christopher D. Richardson,et al. The human CD46 molecule is a receptor for measles virus (Edmonston strain) , 1993, Cell.
[43] D. Gerlier,et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus , 1993, Journal of virology.